Liabilities / Assets
97th percentile
Higher debt load relative to assets than 97% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
1.38x
Liabilities / Revenue
82nd percentile
Higher debt load relative to revenue than 82% of similar nonprofits.
Net Margin
16th percentile
Higher net margin than 16% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
87th percentile
Faster asset growth than 87% of similar nonprofits.
Revenue Growth
47th percentile
Faster revenue growth than 47% of similar nonprofits.
Balance Sheet
Assets
Up$1,661,605
Up $483,937 (+41%) from 2022
Net Assets
Down-$629,349
Down $211,874 (-51%) from 2022
Liabilities
Up$2,290,954
Up $695,811 (+44%) from 2022
Revenue And Expenses
Revenue
Up$3,776,913
Up $180,680 (+5.0%) from 2022
Expenses
Up$4,483,713
Up $984,765 (+28%) from 2022
Net Income
Down-$706,800
Down $804,085 (-827%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Aug 1, 2022 to Jul 31, 2023
Mission and Program Overview
Mission
To recruit the world's best research scientists and clinicians to work together toward an understanding of and the first effective treatments for als (amyotrophic lateral sclerosis) also known as lou gehrig's disease.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $1,661,605
- Liabilities
- $2,290,954
- Net assets
- -$629,349
- Revenue
- $3,776,913
- Expenses
- $4,483,713
- Net income
- -$706,800